Treatment of diabetes mellitus

• US 5,641,744 A
• Filed: 11/17/1994
• Issued: 06/24/1997
• Est. Priority Date: 08/26/1987
• Status: Expired due to Term

• Current Assignee: Astrazeneca Pharmaceuticals LP (Astrazeneca PLC)
• Original Assignee: Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Inventors: Cooper, Garth J. S.
• Primary Examiner(s): Nucker, Christine M.
• Assistant Examiner(s): Prickril, Benet
• Application Number:
  US08/341,342
• Time in Patent Office: 950 Days
• Field of Search: 514/4, 514/12, 530/303
• US Class Current: 514/6.5
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 33/30 Zinc; Compounds thereof
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/225 Calcitonin gene related peptide
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61P 3/08 for glucose homeostasis pancreatic hormones A61P5/48
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 5/48 of the pancreatic hormones
• CPC Class Codes: C07K 14/575 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695

Abstract

The present invention relates to methods of preparing a product or a composition containing amylin or amylin with insulin for treating diabetes mellitus.

Claims

1. A method of preparing a product for treatment of a patient suffering from diabetes mellitus which comprises bringing a predetermined amount of an amylin agonist into the form of a composition suitable for parenteral administration to said diabetic patient.

2. The method of claim 1 wherein said amylin agonist is amylin.

3. The method of claim 1 wherein said amylin agonist is a conservative variant of amylin.

4. The method of claim 2 wherein said amylin is human amylin.

5. The method of claim 1 wherein said amylin agonist is CGRP.

6. The method of claim 1 wherein said amylin agonist is a conservative variant of CGRP.

7. The method of claim 5 wherein said CGRP is human CGRP.

8. The method of claim 1 wherein said parenteral administration is subcutaneous.

9. A method of preparing a composition for treatment of a patient suffering from diabetes mellitus which comprises bringing a predetermined amount of an insulin and a predetermined amount of an amylin agonist into the form of a composition suitable for parenteral administration to said diabetic patient.

10. The method of claim 9 wherein said amylin agonist is amylin.

11. The method of claim 9 wherein said amylin agonist is a conservative variant of amylin.

12. The method of claim 10 wherein said amylin is human amylin.

13. The method of claim 9 wherein said amylin agonist is CGRP.

14. The method of claim 9 wherein said amylin agonist is a conservative variant of CGRP.

15. The method of claim 13 wherein said CGRP is human CGRP.

16. The method of claim 9 wherein said insulin and said amylin agonist are in a ratio of from 100:

1 to 0.1;

1.

17. The method of claim 9 wherein said parenteral administration is subcutaneous.